| Terry L. Murdock |
Terry L. Murdock is currently the Chief Operating Officer at G1 Therapeutics, Inc. He previously worked as the Executive Director-Global Clinical Operations at Ergomed Plc. From 2001 to 2012, he held the position of Senior Vice President-Clinical Operations at ILEX Oncology, Inc. He also served as the VP & Global Head-Oncology Center for Excellence at IQVIA Holdings, Inc. from 2014 to 2017. Prior to that, he was the Vice President-Research at The US Oncology Network from 1995 to 2001. Mr. Murdock completed his undergraduate and graduate degrees at The University of Texas at Austin. |
| Monica Roberts Thomas |
Monica Roberts Thomas is currently working as the General Counsel, Chief Legal & People Officer at G1 Therapeutics, Inc. Previously, she worked as the Head-Corporate Legal at Radius Health, Inc. She completed her undergraduate degree at Duke University and her graduate degree at NCCU School of Law. |
| Garry Allen Nicholson |
Garry Allen Nicholson is currently the Chairman at G1 Therapeutics, Inc. and Day One Biopharmaceuticals, Inc. He is also a Director at XTuit Pharmaceuticals, Inc. and Tmunity Therapeutics, Inc. In his former positions, Mr. Nicholson served as an Independent Director at Five Prime Therapeutics, Inc. from 2017 to 2021. He was also a Director at Tesaro, Inc., Personal Genome Diagnostics, Inc., SQZ Biotechnologies Co., and The Pfizer Foundation, Inc. Additionally, he served as the President-Pfizer Oncology at Pfizer Inc. from 2008 to 2015. Mr. Nicholson obtained his undergraduate degree from The University of North Carolina at Chapel Hill and holds an MBA from the University of South Carolina. |
| Mark Avagliano |
Mark Avagliano is currently the Chief Business Officer at G1 Therapeutics, Inc. Prior to this, he worked at Pfizer Inc. for 15 years as the Vice President & Head-Corporate Development. Avagliano has a graduate degree from the University of Oxford and the London School of Economics & Political Science, and an undergraduate degree from Marist College. |
| John Umstead |
John Umstead is currently the Chief Financial Officer at G1 Therapeutics, Inc. He previously worked as the Director-Emeritus at Monongahela Valley Hospital, Inc. and as the Head-Capital Markets Accounting at PricewaterhouseCoopers LLP. He received a graduate degree from Kenan-Flagler Business School and an undergraduate degree from the University of North Carolina at Chapel Hill. |
| Andrew Perry |
Andrew Perry is currently the Chief Commercial Officer at G1 Therapeutics, Inc. He previously worked as the Vice President of US Marketing at ViiV Healthcare Ltd. Mr. Perry is a graduate of the University of Glasgow and The University of Sheffield. |
| Rajesh K. Malik |
Rajesh K. Malik's current job(s) include being the Director at Meryx, Inc. since 2018 and the Chief Medical Officer at G1 Therapeutics, Inc. since 2014. Dr. Malik's former job(s) include being an Associate Director at Bristol Myers Squibb Co. from 2000 to 2002, an Executive Director at EMD Pharmaceuticals, Inc. from 2002 to 2004, a Director & Chief Medical Officer at Agennix AG from 2007 to 2013, an Independent Director at POINT Biopharma Global, Inc. from 2021 to 2023, and the Chief Medical Officer at Fennec Pharmaceuticals, Inc. from 2004 to 2007. Dr. Malik also held the position of Assistant Professor at the University of Virginia and Chief Medical Officer at Agennix, Inc.Dr. Malik obtained a doctorate degree from the University of Sheffield Medical School. |
| Jack Bailey |
Jack Bailey is currently the President, Chief Executive Officer & Director at G1 Therapeutics, Inc. He is also a Director at UNC Health Care System and Emergo Therapeutics, Inc. Previously, he held positions as a Director at The North Carolina Biotechnology Center and Pharmaceutical Research & Manufacturers of America. He was also a Senior Vice President at Eli Lilly & Co. and served as the President-US Pharmaceuticals at GSK Plc from 2009 to 2019. Mr. Bailey completed his undergraduate degree at Hobart & William Smith Colleges and holds an MBA from The University of North Carolina at Chapel Hill. |
| Cynthia L. Flowers |
Cynthia L. Flowers is currently the Chief Executive Officer at Omeza Holdings, Inc. She also holds positions as an Independent Non-Executive Director at Hikma Pharmaceuticals Plc, an Independent Director at Kadmon Holdings, Inc., an Independent Director at G1 Therapeutics, Inc., a Director at Cyber X Designs LLC, a Director at Relevate Health Group, Inc., an Independent Non-Executive Director at Hikma Ventures Ltd., a Director at Eternatear, Inc., a Director at Relevate Holdings LP, an Independent Director at Lisata Therapeutics, Inc., and a Member of the National Association of Corporate Directors (Virginia). Additionally, Ms. Flowers is the Owner of Eir Advisory LLC. In the past, Ms. Flowers served as the President & Chief Executive Officer at Eisai, Inc. from 2008 to 2010, and as the President & Chief Executive Officer-North America at Ipsen, Inc. from 2014 to 2017. She also held positions as a Director at CenterLight Health System, Inc., an Independent Director at Caladrius Biosciences, Inc., a Director at Sarah Cannon Research Institute LLC from 2010 to 2013, a Director at Nanoform Finland Oyj, and as the Vice President & General Manager-US Oncology at Amgen, Inc. from 2005 to 2008. Additionally, she served as the Senior Vice President-International at Optimer Pharmaceuticals LLC. Ms. Flowers completed her undergraduate studies at the University of Delaware and holds an MBA from The Wharton School of the University of Pennsylvania. |
| Jacks Lee |
Jacks Lee is an Independent Director at G1 Therapeutics, Inc. and Vaxcyte, Inc. He previously worked as a Senior Vice President-Manufacturing & Supply at Merck & Co., Inc. He holds a graduate degree from the University of Central Missouri and an undergraduate degree from the University of Wisconsin. |
| Glenn P. Muir |
Glenn P. Muir is currently serving as an Independent Director at Repligen Corp., Neuronetics, Inc., Impulse Dynamics NV, and G1 Therapeutics, Inc. He is also a Director at Impulse Dynamics Ltd., a Member of The American Institute of Certified Public Accountants, and a Member of the Massachusetts Society of Certified Public Accountants, Inc. In the past, Mr. Muir held positions as a Director at Vivid Technologies, Inc. from 1996 to 1999, a Director at Third Wave Technologies, Inc. in 2008, an External Director at ReWalk Robotics Ltd. from 2014 to 2017, a Director at RainDance Technologies, Inc. from 2014 to 2017, the CFO and EVP-Finance & Administration at Hologic, Inc. from 2013 to 2014, a Senior Auditor at Arthur Andersen LLP from 1981 to 1984, and the CFO and VP-Finance & Administration at Metallon Engineered Materials Corp. from 1986 to 1988. He also served as the Treasurer & Director at UMassFive College Federal Credit Union. Mr. Muir obtained a graduate degree from Bentley University, an undergraduate degree from the University of Massachusetts, and an MBA from Harvard Business School. |
| Alicia Secor |
Alicia Secor is currently the President, Chief Executive Officer & Director at Atalanta Therapeutics, Inc. She is also an Independent Director at G1 Therapeutics, Inc. and a Director at Orchard Therapeutics (Europe) Ltd. Additionally, she serves as a Director at the Foundation For Prader-Willi Research, Inc. In her former roles, Ms. Secor was the President, Chief Executive Officer & Director at Catalent JNP, Inc. from 2016 to 2018. She also served as an Independent Non-Executive Director at GW Pharmaceuticals Ltd. from 2017 to 2021. From 2018 to 2024, she was an Independent Non-Executive Director at Orchard Therapeutics Plc. Prior to that, she held the position of Vice President & GM-Metabolic Diseases at Genzyme Corp. from 1998 to 2013. She was the Chief Commercial Officer at Zafgen, Inc. from 2014 to 2016, and the Chief Operating Officer & Senior Vice President at Synageva BioPharma Corp. in 2013. Ms. Secor holds an MBA from Northeastern University and an MBA from D'Amore-Mckim School of Business. She also has an undergraduate degree from the University of New Hampshire. |
| Norman E. Sharpless |
Norman E. Sharpless was the founder of G1 Therapeutics, Inc. (founded in 2008) where he served as the Director from 2008 to 2015. He previously held the position of Co-Chief Executive Officer at Jupiter Bioventures LLC, Director at CEO Roundtable on Cancer, Inc., Independent Director at G1 Therapeutics, Inc. (since 2022), Director at Karius, Inc. (since 2023), Director at Nucleus Radiopharma, Inc., Member at American Society of Clinical Investigation, and Professor-Cancer Research at The University of North Carolina at Charlotte (since 2013). Previously, he held the position of Director at the National Cancer Institute and the National Institutes of Health (2017-2022), and Director at Lineberger Comprehensive Cancer Center (2014-2017). Dr. Sharpless completed his undergraduate and doctorate degrees at the University of North Carolina at Chapel Hill. |
